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RNA fusions involving CD28 are rare in peripheral 
T-cell lymphomas and concentrate mainly in those
derived from follicular helper T cells
Peripheral T-cell lymphomas (PTCL) comprise usually
aggressive neoplasms of mature T cells with a heteroge-
neous molecular background. Over the past years, sever-
al genomic studies stemming from different research
groups have shown evidence that mutation-induced acti-
vation of the T-cell receptor (TCR) signaling pathway is
involved in the pathogenesis of several PTCL entities.1-7
Notably, recurrent activating point mutations in CD28
which encodes a major TCR costimulatory receptor have
been reported, mainly in angioimmunoblastic T-cell lym-
phoma (AITL) (10-15% of the cases).2,3 Recently, four dif-
ferent ribonucleic acid (RNA) fusions involving the car-
boxy-terminal part of CD28 with the N-terminal part of
CTLA4 or ICOS were discovered by RNA sequencing
analysis of AITL,2,8 cutaneous T-cell lymphoma
(CTCL)4,9,10 and adult T-cell lymphoma/leukemia (ATLL).1
While these data suggest that overall these fusions are
rare (5-11%), a high frequency of CTLA4(ex3)_CD28(ex4)
fusion (38% of the cases) was reported in a cohort of 120
PTCLs from Asia (including 50 AITL, 39 PTCL-not other-
wise specified [-NOS] and 31 extranodal natural killer/T-
cell lymphoma [ENKTCL]) via reverse transcription poly-
merase chain reaction (RT-PCR) analysis of formalin-
fixed paraffin-embedded (FFPE) samples.8 However, by
reanalyzing published whole exome sequencing and
RNA sequencing (RNAseq) data (43 AITL, 16 PTCL-NOS
and 43 ENKTCL), Gong et al. found only one AITL posi-
tive case for the CTLA4(ex3)_CD28(ex4) fusion.11 In order
to clarify these discrepant findings and to assess the
prevalence of all depicted CD28 RNA fusions, we
designed a RT-PCR assay to detect these four CD28
fusions which we then applied to a large series (n=273) of
diagnostic frozen biopsy samples representative of vari-
ous PTCL entities (Figure 1A). We found that these
rearrangements are generally rare in PTCL (prevalence
4.8%), relatively more frequent in follicular helper T
(TFH)-derived entities (6.5%), and most commonly rep-
resented by the ICOS(ex1)_CD28(ex2) fusion (73% of
the cases). 
Our study group comprised 110 AITL and 28 other
nodal lymphomas of TFH derivation (24 TFH-like
PTCL12,13 and four follicular [F]-PTCLs) (Online
Supplementary Figure S1) plus 135 samples of different
PTCL entities (Table 1) collected in the frame of the
genomic network from the Lymphoma Study Association
(LYSA).14 Samples were divided equally between our two
laboratories for molecular screening. RT-PCR amplifica-
tions of the CD28 fusions and ACTB (internal control) on
total messenger (m)RNAs extracted from frozen tumor
samples were analyzed by agarose gel electrophoresis
(Online Supplementary Figure S2). All positive cases (n=13)
and a subset of negative cases (n=58; 22%) were cross
validated in both laboratories.
Results are summarized in Table 1. Overall, CD28
fusions were detected in 13/273 (4.8%) cases. Among
primarily nodal PTCLs, the highest prevalence was found
in the group of AITL and other TFH-derived neoplasms
with 9/138 positive samples (6/110 AITL, 3/24 TFH-like
PTCL and none of the four F-PTCL; 6.8% in total), only
2/63 PTCL-NOS (3.2%) harbored a fusion, while no
fusions were detected in any of the ALCLs (n=9). One of
26 CTCL and 1/6 ATLL cases were found to be positive.
None of the non-cutaneous extranodal PTCL tested (18
ENKTCL, ten enteropathy associated T-cell lymphoma
[EATL], three hepatosplenic T-cell lymphoma [HSTL])
were positive. A total of 15 fusions were amplified; the
most common rearrangement being
ICOS(ex1)_CD28(ex2) (11/15; 73% of the fusions), fol-
lowed by CTLA4(ex3)_CD28(ex4) (3/15 fusions) while
CTLA4(ex2)_CD28(ex4) was identified in a single CTCL
sample. Interestingly, two cases (one TFH-derived PTCL
and one CTCL) harbored two different CD28 RNA
fusions, an observation previously made in one ATLL
sample.1
All CD28 chimeric proteins are expected to comprise
the cytoplasmic portion of CD28, accounting for signal
transduction and a part or the totality of the transmem-
brane and extracellular domains of CTLA4, ICOS or
CD28 (Figure 1A). Depending on the fusion partner, their
expression is under the control of the regulatory elements
of CTLA4 or ICOS.1,8 In normal T cells, following TCR
activation, CD28 expression is downregulated while the
expression of CTLA4 and ICOS is induced.15 In neoplastic
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Table 1. Distribution of CD28 RNA fusions detected by RT-PCR in different peripheral T-cell lymphoma entities. 
All fusions CTLA4(ex3)_ CTLA4(ex1)_ CTLA4(ex2)_ ICOS(ex1)_ Dual
CD28(ex4) CD28(ex2) CD28(ex4) CD28(ex2) fusions
All PTCLs (273) 13/273 (4.8%) 3/273 0/273 1/273 11/273 2/273
AITL (110) TFH-like PTCL (24) 9/138 (6.5%) 2/138 0/138 0/138 8/138 1/138*
F-PTCL (4)
PTCL, NOS (63) 2/63 (3.1%) 0/63 0/63 0/63 2/63 0/63
ALCL (9) 0/9 (0%) 0/9 0/9 0/9 0/9 0/9
ENKTCL (18) 0/18 (0%) 0/18 0/18 0/18 0/18 0/18
EATL (10) 0/10 (0%) 0/10 0/10 0/10 0/10 0/10
HSTL (3) 0/3 (0%) 0/3 0/3 0/3 0/3 0/3
CTCL (26) 1/26 (3.8%) 1/26 0/26 1/26 0/26 1/26
ATLL (6) 1/6 (17%) 0/6 0/6 0/6 1/6 0/6
*This case harbored CTLA4(ex3)_CD28(ex4) and  ICOS(ex1)_CD28(ex2) RNA fusions. PTCL: peripheral T-cell lymphoma; AITL: angioimmunoblastic T-cell lymphoma; TFH-
like PTCL: follicular helper T-cell like PTCL; F-PTCL: follicular PTCL; PTCL, NOS : PTCL, not otherwise specified; ALCL: anaplastic large cell lymphoma; ENKTCL: extranodal
natural killer/T-cell lymphoma, nasal-type; EATL: enteropathy associated T-cell lymphoma; HSTL: hepatosplenic T-cell lymphoma; CTCL: cutaneous T-cell lymphoma; ATLL :
adult T-cell lymphoma/leukemia.
cells harboring CD28 fusions, it can be anticipated that
signals which normally induce the expression of CTLA4
or ICOS, would induce the expression of the fusion pro-
teins whose triggering mimics CD28 signalling. Thus, the
overall consequence of these fusions would be continu-
ous or prolonged CD28 co-stimulatory signaling. It has
been demonstrated that Jurkat cells transduced with the
CTLA4(ex3)_CD28(ex4) fusion showed enhanced prolif-
eration and interleukin (IL)-2 production upon CTLA4
binding.8,9 To further investigate the signaling induced by
the ICOS(ex1)_CD28(ex2) fusion, we used a nuclear fac-
tor k-light-chain-enhancer of activated B cells (NF-kB)
luciferase-based reporter assay to assess its activity in
comparison to mutant (T195P) and wild-type CD28
(Figure 1B). The chimeric protein is composed of the
ICOS signal peptide fused to the extracellular, transmem-
brane and cytoplasmic domains of CD28. In the mature
form, the signal peptide is cleaved, resulting in CD28
expression at the cell surface. Upon CD3 and CD28 co-
stimulation, CD28_T195P induced higher levels of
luciferase expression than CD28_WT (P=0.01) (as previ-
ously described),2 while the ICOS(ex1)_CD28(ex2) fusion
delivered an activatory signal similar in amplitude to that
of the CD28_WT form (Figure 1B).
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Figure 1. Biological impact of CD28
alterations. (A) Schematic represen-
tation of the different CD28 RNA
fusions and PCR design for their
screening. Arrows indicate the
approximate positions of oligonu-
cleotide primers on the indicated
RNA fusions. (B) NF-kB luciferase
reporter assay in Jurkat cells moni-
toring the activity of a CD28 T195P
activating mutant and the
ICOS(ex1)_CD28(ex2) fusion, com-
pared with CD28 WT. Data are rep-
resented as mean+/-SEM from four
independent experiments. (C)
Spider plot representation of gene
sets differentially enriched in
patients with (red) (n=14) or without
(blue) (n=84) alterations (mutations
or fusions) in CD28. A total of 304
signatures, including 23 of 50 hall-
mark signatures and nine signa-
tures from the curated and immuno-
genic signature collection of the
Molecular Signatures Database
(MSigDB), all signatures of interest
in lymphoid biology (Signatures
database, Staudt's lab), and two
manually annotated sequences
linked to TCR signalling were tested.
The list of signatures that reached
statistical significance is provided in
Online Supplementary Table S2. WT:
wild-type; Mut/Fus: mutations or
fusions.
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Taking advantage of available transcript profiles for a
large subset of AITL and other TFH lymphomas, we
sought to assess the impact of CD28 genetic alterations
(mutations and fusions) on gene expression (Figure 1C
and Online Supplementary Figure S2). No significant differ-
ence in CD28, CTLA4 or ICOS mRNA levels was
observed between six fusion-positive and 96 fusion-neg-
ative cases which had associated gene expression profil-
ing data. Next, considering those samples harboring
CD28 mutations or fusions (referred to as
CD28_Mut/Fus) together versus those wild-type (WT) for
CD28, the analysis of the top 100 genes differentially
expressed showed the up-regulation of genes involved in
PI3K, MAPK or NF-kB signalling pathways, in actin
cytoskeleton remodeling, in metabolism or apoptosis in
CD28_Mut/Fus cases (Online Supplementary Figure S3).
Accordingly, gene set enrichment analyses (GSEA)
showed that the molecular signatures of CD28_Mut/Fus
were differentially enriched in 20 gene sets as compared
to CD28_WT, reflecting higher T-cell activation, prolifer-
ation or metabolic activity (Figure 1C and Online
Supplementary Table S2).
We then examined how CD28 fusions integrate into
the mutational landscape and impact outcome in AITL
and other PTCLs of TFH derivation. Figure 2A depicts the
distribution of CD28 alterations and mutations in other
TCR signaling-related genes (subsequently called TCR-
related genes), RHOA and epigenetic modifiers (TET2
DNMT3A or IDH2) in the entire cohort of AITL, TFH-like
PTCLs and F-PTCLs tested for CD28 fusions (138 cases in
total). CD28 fusions (9/138) and point mutations
(11/138) were mutually exclusive and altogether present
in 15% of the samples. While the majority of CD28 point
mutations (10/11 cases, 91%) were found in AITL, six of
nine CD28 RNA fusions (67%) were present in other
TFH PTCLs. CD28 mutations were mainly found in
RHOA-mutated cases (10/11; 91%), but were virtually
exclusive to mutations in other TCR-related genes (9/11;
82%). Conversely, CD28 fusions co-occurred with RHOA
mutations in only three of nine cases (33%) whereas four
of nine fusion-positive cases (44%) had mutations in
other TCR-related genes.
The 84 patients who received intent-to-treat anthracy-
clin-based induction chemotherapy were considered for
clinical outcome analysis. Of these, seven patients had
CD28 mutations and six harbored a CD28 fusion. Of six
CD28 fusion-positive patients, five relapsed and four died
within the first year after diagnosis (two from disease,
one from treatment toxicity and one from unknown
causes). Considering 13 CD28_Mut/Fus versus 71 CD28
WT patients, no significant difference was observed in
overall survival (OS) or progression free survival (PFS)
(Figure 2B). However, focusing on the subset of 59 TFH-
derived PTCL previously characterized for mutations in a
large panel of TCR-related genes who received an anthra-
cyclin based regimen, three patients  carrying at least one
alteration (mutation or fusion) in one or more gene(s)
related to TCR signalling other than RHOA
(TCR_Mut/Fus), (36 patients, 61%) showed a trend
towards shorter PFS (P=0.07) compared to other patients
who carried RHOA mutations only (RHOA_Mut) (14
patients, 24%) or were WT for all tested genes
(TCR_WT) (nine patients, 15%) (Online Supplementary
Figure S4). These data expand our previous findings of
the negative connotation of these alterations on patient
outcome.
In conclusion, our findings definitively confirm that the
CD28 RNA fusions with CTLA4 or ICOS are overall rare
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Figure 2. CD28 mutations and fusions in AITL and other TFH-derived PTCLs. (A) Landscape of genetic alterations of CD28, other TCR signaling-related (PLCG1,
CTNNB1, GTF2I, PIK3R1, PDPK1, VAV1, FYN, CARD11, KRAS; STAT3, LCK, TRAF6, AKT1, PIK3R5, VAV2, MAPK3, PIK3CA), RHOA, and epigenetic modifiers (TET2,
DNMT3A or IDH2) in 138 AITL and other PTCLs of TFH derivation. (B) Overall survival (OS; left panel) and progression-free survival (PFS; right panel) of patients
with (red) or without (blue) CD28 mutations or fusions. Analyses are restricted to the 84 patients with AITL or other PTCLs of TFH derivation treated with anthra-
cyclin-based chemotherapy. TFH-like PTCL: follicular helper T-cell like peripheral T-cell lymphoma; F-PTCL: follicular PTCL; AITL: angioimmunoblastic T-cell lym-
phoma.
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events in PTCL (4.8%). This is unambiguously demon-
strated by the screening of a large cohort of frozen cases
in two different laboratories. Specifically, the prevalence
of the CTLA4(ex3)_CD28(ex4) fusion (found in two TFH-
PTCLs and one CTCL) was only 1% in our cohort. The
most common fusion was ICOS(ex1)_CD28(ex2) (73%
of fusions), which was previously reported in one out of
20 AITL cases subjected to  RNAseq.2 In AITL and other
TFH-derived PTCL, where these fusions are most preva-
lent (6.5% of cases), they are mutually exclusive to CD28
mutations. Thus, taking into account both point muta-
tions and fusions, CD28 ranks second after RHOA among
the altered TCR-related gene in the group of PTCLs of
TFH derivation, found in 15% of the patients.
Considering the patients with mutations in TCR-related
genes other than RHOA, 29% of them harbor CD28 alter-
ations. Finally, within the limit of this retrospective
series, the cases harboring CD28 Mut/Fus did not differ
from others in terms of OS or PFS,  and had gene expres-
sion programming (GEP) enriched in signatures reflecting
higher T-cell activation and higher proliferation.
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